{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:55:22Z","timestamp":1784602522036,"version":"3.55.0"},"reference-count":62,"publisher":"The Editorial Committee of Annals of Vascular Diseases","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Vascular Diseases","Ann Vasc Dis","AVD"],"published-print":{"date-parts":[[2022,12,25]]},"DOI":"10.3400\/avd.ra.22-00086","type":"journal-article","created":{"date-parts":[[2022,10,2]],"date-time":"2022-10-02T22:21:13Z","timestamp":1664749273000},"page":"241-252","source":"Crossref","is-referenced-by-count":8,"title":["Therapeutic Angiogenesis Using Autologous CD34-Positive Cells for Vascular Diseases"],"prefix":"10.3400","volume":"15","author":[{"given":"Yasuyuki","family":"Fujita","sequence":"first","affiliation":[{"name":"Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation at Kobe"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhiko","family":"Kawamoto","sequence":"additional","affiliation":[{"name":"Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation at Kobe"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1983","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Civin CI, Strauss LC, Brovall C, et al. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 1984; <b>133<\/b>: 157-65.","DOI":"10.4049\/jimmunol.133.1.157"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Sidney LE, Branch MJ, Dunphy SE, et al. Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem Cells 2014; <b>32<\/b>: 1380-9.","DOI":"10.1002\/stem.1661"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; <b>275<\/b>: 964-7.","DOI":"10.1126\/science.275.5302.964"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Gehling UM, Ergun S, Schumacher U, et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 2000; <b>95<\/b>: 3106-12.","DOI":"10.1182\/blood.V95.10.3106.010k08_3106_3112"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Ii M, Nishimura H, Iwakura A, et al. Endothelial progenitor cells are rapidly recruited to myocardium and mediate protective effect of ischemic preconditioning via \u201cimported\u201d nitric oxide synthase activity. Circulation 2005; <b>111<\/b>: 1114-20.","DOI":"10.1161\/01.CIR.0000157144.24888.7E"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Jujo K, Ii M, Losordo DW. Endothelial progenitor cells in neovascularization of infarcted myocardium. J Mol Cell Cardiol 2008; <b>45<\/b>: 530-44.","DOI":"10.1016\/j.yjmcc.2008.08.003"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Miyamoto Y, Suyama T, Yashita T, et al. Bone marrow subpopulations contain distinct types of endothelial progenitor cells and angiogenic cytokine-producing cells. J Mol Cell Cardiol 2007; <b>43<\/b>: 627-35.","DOI":"10.1016\/j.yjmcc.2007.08.001"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; <b>9<\/b>: 654-9.","DOI":"10.1038\/ncb1596"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Sahoo S, Klychko E, Thorne T, et al. Exosomes from human CD34(+) stem cells mediate their proangiogenic paracrine activity. Circ Res 2011; <b>109<\/b>: 724-8.","DOI":"10.1161\/CIRCRESAHA.111.253286"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Yoon YS, Park JS, Tkebuchava T, et al. Unexpected severe calcification after transplantation of bone marrow cells in acute myocardial infarction. Circulation 2004; <b>109<\/b>: 3154-7.","DOI":"10.1161\/01.CIR.0000134696.08436.65"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kawamoto A, Iwasaki H, Kusano K, et al. CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells. Circulation 2006; <b>114<\/b>: 2163-9.","DOI":"10.1161\/CIRCULATIONAHA.106.644518"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Masuda H, Alev C, Akimaru H, et al. Methodological development of a clonogenic assay to determine endothelial progenitor cell potential. Circ Res 2011; <b>109<\/b>: 20-37.","DOI":"10.1161\/CIRCRESAHA.110.231837"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013; <b>382<\/b>: 1329-40.","DOI":"10.1016\/S0140-6736(13)61249-0"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007; <b>45<\/b> <b>Suppl S<\/b>: S5-67.","DOI":"10.1016\/j.jvs.2006.12.037"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Aboyans V, Ricco JB, Bartelink MEL, et al. Editor\u2019s choice\u20142017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2018; <b>55<\/b>: 305-68.","DOI":"10.1016\/j.ejvs.2018.03.004"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Fadini GP, Agostini C, Avogaro A. Autologous stem cell therapy for peripheral arterial disease: meta-analysis and systematic review of the literature. Atherosclerosis 2010; <b>209<\/b>: 10-7.","DOI":"10.1016\/j.atherosclerosis.2009.08.033"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Sprengers RW, Moll FL, Verhaar MC. Stem cell therapy in PAD. Eur J Vasc Endovasc Surg 2010; <b>39<\/b> <b>Suppl 1<\/b>: S38-43.","DOI":"10.1016\/j.ejvs.2009.12.001"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Kalka C, Masuda H, Takahashi T, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 2000; <b>97<\/b>: 3422-7.","DOI":"10.1073\/pnas.97.7.3422"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Murohara T, Ikeda H, Duan J, et al. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J Clin Invest 2000; <b>105<\/b>: 1527-36.","DOI":"10.1172\/JCI8296"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Kawamoto A, Katayama M, Handa N, et al. Intramuscular transplantation of G-CSF-mobilized CD34(+) cells in patients with critical limb ischemia: a phase I\/IIa, multicenter, single-blinded, dose-escalation clinical trial. Stem Cells 2009; <b>27<\/b>: 2857-64.","DOI":"10.1002\/stem.207"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Kinoshita M, Fujita Y, Katayama M, et al. Long-term clinical outcome after intramuscular transplantation of granulocyte colony stimulating factor-mobilized CD34 positive cells in patients with critical limb ischemia. Atherosclerosis 2012; <b>224<\/b>: 440-5.","DOI":"10.1016\/j.atherosclerosis.2012.07.031"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Fujita Y, Kinoshita M, Furukawa Y, et al. Phase II clinical trial of CD34+ cell therapy to explore endpoint selection and timing in patients with critical limb ischemia. Circ J 2014; <b>78<\/b>: 490-501.","DOI":"10.1253\/circj.CJ-13-0864"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Ohtake T, Mochida Y, Ishioka K, et al. Autologous granulocyte colony-stimulating factor-mobilized peripheral blood CD34 positive cell transplantation for hemodialysis patients with critical limb ischemia: a prospective phase II clinical trial. Stem Cells Transl Med 2018; <b>7<\/b>: 774-82.","DOI":"10.1002\/sctm.18-0104"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Tanaka R, Masuda H, Kato S, et al. Autologous G-CSF-mobilized peripheral blood CD34+ cell therapy for diabetic patients with chronic nonhealing ulcer. Cell Transplant 2014; <b>23<\/b>: 167-79.","DOI":"10.3727\/096368912X658007"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Losordo DW, Kibbe MR, Mendelsohn F, et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circ Cardiovasc Interv 2012; <b>5<\/b>: 821-30.","DOI":"10.1161\/CIRCINTERVENTIONS.112.968321"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Dong Z, Pan T, Fang Y, et al. Purified CD34(+) cells versus peripheral blood mononuclear cells in the treatment of angiitis-induced no-option critical limb ischaemia: 12-month results of a prospective randomised single-blinded non-inferiority trial. EBioMedicine 2018; <b>35<\/b>: 46-57.","DOI":"10.1016\/j.ebiom.2018.08.038"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; <b>361<\/b>: 13-20.","DOI":"10.1016\/S0140-6736(03)12113-7"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Bekkers SC, Smulders MW, Passos VL, et al. Clinical implications of microvascular obstruction and intramyocardial haemorrhage in acute myocardial infarction using cardiovascular magnetic resonance imaging. Eur Radiol 2010; <b>20<\/b>: 2572-8.","DOI":"10.1007\/s00330-010-1849-9"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Ito H, Tomooka T, Sakai N, et al. Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992; <b>85<\/b>: 1699-705.","DOI":"10.1161\/01.CIR.85.5.1699"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Kocher AA, Schuster MD, Szabolcs MJ, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001; <b>7<\/b>: 430-6.","DOI":"10.1038\/86498"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Kawamoto A, Gwon HC, Iwaguro H, et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 2001; <b>103<\/b>: 634-7.","DOI":"10.1161\/01.CIR.103.5.634"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Hofmann M, Wollert KC, Meyer GP, et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 2005; <b>111<\/b>: 2198-202.","DOI":"10.1161\/01.CIR.0000163546.27639.AA"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Quyyumi AA, Waller EK, Murrow J, et al. CD34(+) cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent. Am Heart J 2011; <b>161<\/b>: 98-105.","DOI":"10.1016\/j.ahj.2010.09.025"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Quyyumi AA, Vasquez A, Kereiakes DJ, et al. PreSERVE-AMI: a randomized, double-blind, placebo-controlled clinical trial of intracoronary administration of autologous CD34+ cells in patients with left ventricular dysfunction post STEMI. Circ Res 2017; <b>120<\/b>: 324-31.","DOI":"10.1161\/CIRCRESAHA.115.308165"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Mukherjee D, Bhatt DL, Roe MT, et al. Direct myocardial revascularization and angiogenesis\u2014how many patients might be eligible? Am J Cardiol 1999; <b>84<\/b>: 598-600, A8.","DOI":"10.1016\/S0002-9149(99)00387-2"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Lenzen M, Scholte op Reimer W, Norekv\u00e5l TM, et al. Pharmacological treatment and perceived health status during 1-year follow up in patients diagnosed with coronary artery disease, but ineligible for revascularization: results from the Euro Heart Survey on coronary revascularization. Eur J Cardiovasc Nurs 2006; <b>5<\/b>: 115-21.","DOI":"10.1016\/j.ejcnurse.2006.01.003"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Williams B, Menon M, Satran D, et al. Patients with coronary artery disease not amenable to traditional revascularization: prevalence and 3-year mortality. Catheter Cardiovasc Interv 2010; <b>75<\/b>: 886-91.","DOI":"10.1002\/ccd.22431"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Henry TD, Satran D, Hodges JS, et al. Long-term survival in patients with refractory angina. Eur Heart J 2013; <b>34<\/b>: 2683-8.","DOI":"10.1093\/eurheartj\/eht165"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Kawamoto A, Tkebuchava T, Yamaguchi J, et al. Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation 2003; <b>107<\/b>: 461-8.","DOI":"10.1161\/01.CIR.0000046450.89986.50"},{"key":"40","unstructured":"40) Losordo DW, Schatz RA, White CJ, et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I\/IIa double-blind, randomized controlled trial. Circulation 2007; <b>115<\/b>: 3165-72."},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Losordo DW, Henry TD, Davidson C, et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res 2011; <b>109<\/b>: 428-36.","DOI":"10.1161\/CIRCRESAHA.111.245993"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Henry TD, Schaer GL, Traverse JH, et al. Autologous CD34(+) cell therapy for refractory angina: 2-year outcomes from the ACT34-CMI study. Cell Transplant 2016; <b>25<\/b>: 1701-11.","DOI":"10.3727\/096368916X691484"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Povsic TJ, Junge C, Nada A, et al. A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study. Am Heart J 2013; <b>165<\/b>: 854-61.e2.","DOI":"10.1016\/j.ahj.2013.03.003"},{"key":"44","unstructured":"44) Povsic TJ, Henry TD, Traverse JH, et al. The RENEW trial: efficacy and safety of intramyocardial autologous CD34(+) cell administration in patients with refractory angina. JACC Cardiovasc Interv 2016; <b>9<\/b>: 1576-85."},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Henry TD, Losordo DW, Traverse JH, et al. Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials. Eur Heart J 2018; <b>39<\/b>: 2208-16.","DOI":"10.1093\/eurheartj\/ehx764"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Allman KC, Shaw LJ, Hachamovitch R, et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002; <b>39<\/b>: 1151-8.","DOI":"10.1016\/S0735-1097(02)01726-6"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011; <b>364<\/b>: 1607-16.","DOI":"10.1056\/NEJMoa1100356"},{"key":"48","unstructured":"48) Bonow RO, Maurer G, Lee KL, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 2011; <b>364<\/b>: 1617-25."},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Poglajen G, Sever M, Cukjati M, et al. Effects of transendocardial CD34+ cell transplantation in patients with ischemic cardiomyopathy. Circ Cardiovasc Interv 2014; <b>7<\/b>: 552-9.","DOI":"10.1161\/CIRCINTERVENTIONS.114.001436"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Schultheiss HP, Fairweather D, Caforio ALP, et al. Dilated cardiomyopathy. Nat Rev Dis Primers 2019; <b>5<\/b>: 32.","DOI":"10.1038\/s41572-019-0084-1"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Vrtovec B, Poglajen G, Sever M, et al. CD34+ stem cell therapy in nonischemic dilated cardiomyopathy patients. Clin Pharmacol Ther 2013; <b>94<\/b>: 452-8.","DOI":"10.1038\/clpt.2013.134"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Vrtovec B, Poglajen G, Sever M, et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. J Card Fail 2011; <b>17<\/b>: 272-81.","DOI":"10.1016\/j.cardfail.2010.11.007"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Vrtovec B, Poglajen G, Lezaic L, et al. Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circ Res 2013; <b>112<\/b>: 165-73.","DOI":"10.1161\/CIRCRESAHA.112.276519"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Lezaic L, Socan A, Poglajen G, et al. Intracoronary transplantation of CD34(+) cells is associated with improved myocardial perfusion in patients with nonischemic dilated cardiomyopathy. J Card Fail 2015; <b>21<\/b>: 145-52.","DOI":"10.1016\/j.cardfail.2014.11.005"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Vrtovec B, Poglajen G, Lezaic L, et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation 2013; <b>128<\/b> <b>Suppl 1<\/b>: S42-9.","DOI":"10.1161\/CIRCULATIONAHA.112.000230"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Vrtovec B, Poglajen G, Sever M, et al. Effects of repetitive transendocardial CD34(+) cell transplantation in patients with nonischemic dilated cardiomyopathy. Circ Res 2018; <b>123<\/b>: 389-96.","DOI":"10.1161\/CIRCRESAHA.117.312170"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Taguchi A, Soma T, Tanaka H, et al. Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest 2004; <b>114<\/b>: 330-8.","DOI":"10.1172\/JCI200420622"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Ogawa Y, Okinaka Y, Kikuchi-Taura A, et al. Pre-clinical proof of concept: intra-carotid injection of autologous CD34-positive cells for chronic ischemic stroke. Front Med (Lausanne) 2022; <b>9<\/b>: 681316.","DOI":"10.3389\/fmed.2022.681316"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Banerjee S, Bentley P, Hamady M, et al. Intra-arterial immunoselected CD34+ stem cells for acute ischemic stroke. Stem Cells Transl Med 2014; <b>3<\/b>: 1322-30.","DOI":"10.5966\/sctm.2013-0178"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Chen DC, Lin SZ, Fan JR, et al. Intracerebral implantation of autologous peripheral blood stem cells in stroke patients: a randomized phase II study. Cell Transplant 2014; <b>23<\/b>: 1599-612.","DOI":"10.3727\/096368914X678562"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Kuroda R, Matsumoto T, Niikura T, et al. Local transplantation of granulocyte colony stimulating factor-mobilized CD34+ cells for patients with femoral and tibial nonunion: pilot clinical trial. Stem Cells Transl Med 2014; <b>3<\/b>: 128-34.","DOI":"10.5966\/sctm.2013-0106"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Nakamura T, Torimura T, Iwamoto H, et al. CD34(+) cell therapy is safe and effective in slowing the decline of hepatic reserve function in patients with decompensated liver cirrhosis. J Gastroenterol Hepatol 2014; <b>29<\/b>: 1830-8.","DOI":"10.1111\/jgh.12622"}],"container-title":["Annals of Vascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/avd\/15\/4\/15_ra.22-00086\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T04:24:28Z","timestamp":1672460668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/avd\/15\/4\/15_ra.22-00086\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,25]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.3400\/avd.ra.22-00086","relation":{},"ISSN":["1881-641X","1881-6428"],"issn-type":[{"value":"1881-641X","type":"print"},{"value":"1881-6428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,25]]},"article-number":"ra.22-00086"}}